Omni Bio Pharmaceutical, Inc. (OTCBB: OMBP) is an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, such as Type 1 diabetes, graft versus host disease and chronic gout.
The Company’s propriety technology platform, AAT-Fc, is a first-in-class recombinant version of the naturally occurring human protein alpha-1 antitrypsin (AAT), which has demonstrated profound anti-inflammatory and tissue protective effects in preclinical and early human clinical studies.
Omni Bio is uniquely positioned to capitalize on the rapidly expanding market for AAT, which emerging scientific and clinical evidence now suggests could address multiple high-value disease indications characterized by inflammation and/or immune system defects. While AAT extracted from donated human plasma (p-AAT) has been commercialized safely as an intravenous supplementation therapy for AAT-deficient individuals for more than 25 years, it cannot be produced efficiently at the scale required to meet this growing demand.
Omni Bio’s unique recombinant AAT-Fc can offer several potential advantages over current p-AAT products, including superior potency, longer half-life, improved safety and easy-to-administer subcutaneous dosing, as well as significantly enhanced manufacturing scalability. The company intends to exploit this enhanced product potential to develop first-in-class therapeutics to address a broad array of new clinical opportunities.
Bruce Schneider, Ph.D. - Chief Executive OfficerDr. Schneider has served as our CEO and a member of our Board of Directors since January 1, 2013. Since 2010, he has provided R&D executive advisory and business development services to several large and small pharmaceutical companies, including an extensive role with Pfizer where he was engaged to facilitate strategic planning and decision-making for its early drug development pipeline. From 2009 to 2010, he was employed by Pfizer as Executive Vice President & R&D Integration Lead. From 1972-2009, he was employed by Wyeth Research, which was acquired by Pfizer in 2009, where he held numerous senior-level R&D positions, including Executive Vice President & Chief of Operations (2002 to 2009), Senior Vice President, Research Operations & Planning (1992-2002) and Vice President, Worldwide Clinical Operations (1987-1992). Dr. Schneider holds a Ph.D. in Applied Statistics from Temple University and a Sc.B in Applied Mathematics from Brown University.
Jack Riccardi, MBA - Chief Financial OfficerMr. Riccardi brings more than 30 years of financial leadership experience. He was formerly CFO of ADial Pharmaceuticals and served most recently as CFO and Partner at Green Street Ventures. Mr. Riccardi's appointment will become effective on September 1, 2014. Prior to his role at Green Street Ventures, Mr. Riccardi served as Chief Financial Officer, Treasurer and Secretary of ADial Pharmaceuticals, where he oversaw the commercialization effort, drug market studies, and advanced valuation analyses for several late stage pharmacotherapies. He also served as Chief Financial Officer of Modern Visuals, a software start-up venture spun off from Siemens Technology Group, where he successfully prepared the company for its eventual sale to a strategic buyer. Mr. Riccardi spent eight years at General Motors, last serving as Director, Strategic Planning. While at GM, Jack initiated content acquisition and strategic alliance efforts expanding GM's OnStar brand into new household markets, established the company's corporate technology venture fund for direct investment into promising technologies, and founded the company's Business Development Forum.
Charles Dinarello, MD - Chief Scientific OfficerDr. Dinarello has served as our Chief Scientific Officer and Director of Medical Affairs since February 2011. He also serves on our Scientific Advisory Board. From March 2009 to February 2011, he served as our Acting Chief Executive Officer and a member of our Board of Directors. Previously Professor of Medicine at Tufts University in Boston, since 1996, he is Professor of Medicine and Immunology at the University of Colorado Denver. Dr. Dinarello has published over 700 original research articles on cytokines, particularly interleukin-1 (IL-1) and tumor necrosis factor, and is considered a “founding father” of cytokine biology. Dr. Dinarello currently serves as a director of Techne Corporation (NASDAQ NNM: TECH), and is a Scientific Advisory Board member of Senesco Technologies, Inc., Source MDx, Inc., GlobeImmune, Inc., and Capstone Pharmaceuticals, Inc. He is also a member of the editorial board of the Proceedings of the National Academy of Sciences. Dr. Dinarello has received numerous international awards for his scientific contributions in cytokine biology.
Bruce Forrest, MD - Chief Development OfficerDr. Forrest was appointed to serve as our CDO in May, 2014. Concurrently he is President of B D Forrest & Company, Inc. a biopharmaceutical consulting firm that provides scientific strategy and business development support to emerging and established pharmaceutical companies. The Company retained Dr. Forrest to provide such services from late 2012 through April 2014. In his expanded role of Chief Development Officer he will now also oversee implementation of the development plan for Fc-AAT. Dr. Forrest has over 25 years of industry experience in pharmaceutical development, including vaccines and biopharmaceuticals. He was previously Senior Vice President in Vaccines R&D at Wyeth Pharmaceuticals where he was responsible for clinical and development activities for all late phase programs. From 2004-2008 he was head of Wyeth’s R&D organization in Japan where he oversaw the successful regulatory approvals of several new drug entities. He previously worked in various clinical research roles at Chiron Corporation and United Biomedical, Inc. Dr. Forrest is a medical graduate (MD) from the University of Adelaide (Australia) where he specialized in immunology and has an MBA from the Warwick Business School (UK).
Bruce Schneider, Ph.D., Chairperson
Dr. Schneider has served as our CEO and a member of our Board of Directors since January 1, 2013. Since 2010, he has provided R&D executive advisory and business development services to several large and small pharmaceutical companies, including an extensive role with Pfizer where he was engaged to facilitate strategic planning and decision-making for its early drug development pipeline. From 2009 to 2010, he was employed by Pfizer as Executive Vice President & R&D Integration Lead. From 1972-2009, he was employed by Wyeth Research, which was acquired by Pfizer in 2009, where he held numerous senior-level R&D positions, including Executive Vice President & Chief of Operations (2002 to 2009), Senior Vice President, Research Operations & Planning (1992-2002) and Vice President, Worldwide Clinical Operations (1987-1992). Dr. Schneider holds a Ph.D. in Applied Statistics from Temple University and a Sc.B in Applied Mathematics from Brown University.
Michael Kamarck, Ph.D.
Michael Kamarck has served as a member of our Board of Directors since January 2013. From 2010 to 2012, Dr. Kamarck was employed by Merck as President of Merck BioVentures and Senior Vice President of Vaccines and Biologics Manufacturing. From 2001 to 2009, he was employed by Wyeth, where he held various senior executive positions, including President, Technical Operations and Product Supply and was responsible for global technical operations for all of the Wyeth businesses. Dr. Kamarck also served as a member of the Wyeth Management Committee. Prior to Wyeth, he was employed by Bayer AG for 17 years in a variety of technical and leadership capacities. Dr. Kamarck received his B.A. from Oberlin College, his Ph.D. from MIT and was a Leukemia Society Fellow at Yale University.
Albert Kramer has served as a member of our Board of Directors since March 2009. From April 2008 until March 2009, he was a director of Apro Bio Pharmaceutical Corporation. Since 1993, Mr. Kramer has served as an attorney with the Kramer Law Firm. From 1993 to 2005, Mr. Kramer served as Special Counsel to Syratech Corporation. From 2004 to 2008, he served as Chief Counsel to Travelers Marketing, LLC. From 1975 to 1992, Mr. Kramer served as a District Court Judge for the Massachusetts Trial Court. He received his undergraduate and law degrees from Boston University.
Michael Wort has served as a member of our Board of Directors since March 2009, and is a founder of Apro Bio Pharmaceutical Corporation. From October 2008 until March 2009, he was a director of Apro Bio and from October 2008 through December 2008, he served as its Interim Chief Executive Officer. Since 2007, Mr. Wort has served as the Managing Director of De Facto Communications, a subsidiary of Chime Communications, which is listed on the London Stock Exchange. In 2004, Mr. Wort founded MC BioCommunications, an investor and public relations firm specializing in emerging bioscience companies. He is also a founder and director of BeckPharma Limited, a technology transfer company, and PharmScape, a biotechnology consultancy company, both of which were founded in 2003. Mr. Wort’s other prior experience includes various sales, marketing and general management positions with GlaxoSmithKline plc. Additionally, he has served as an advisor and consultant on fund raising for more than 15 small-cap, biotechnology companies. Mr. Wort received his BSC in Applied Biology and is a Chartered Graduate Biologist in Industrial Microbiology.
Sandra Wrobel has served as a member of our Board of Directors since July 2013. Ms. Wrobel is currently CEO and Managing Director, Applied Strategies Consulting, LLC, a firm that provides strategy, business process, and operations expertise to life sciences and global healthcare organizations. She previously served as CFO and Vice President Business Operations at Intrabiotics Pharmaceuticals, Inc. and held a series of positions over twelve years at Strategic Decisions Group, culminating in Managing Director of their Life Sciences Consulting Practice. Ms. Wrobel received her B.S. degree in Chemical & Petroleum Refining Engineering from the Colorado School of Mines and her MBA from the Stanford University Graduate School of Business.